#GramNegativeBacteremia
LightNews LightNews
jama.com
Among patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day clinical outcomes compared with standard testing, despite providing faster guidance for antibiotic escalation or deescalation.

#ESCMIDGlobal2026

ja.ma/4sF52lG
JAMA study: Rapid antimicrobial susceptibility testing (AST) vs. standard AST for bloodstream infections. Conclusion: rapid AST wasn't superior. Population: 486 males, 364 females, median age 72. Intervention: text@1, text@2. Findings: alive at 30 days, similar rates.
April 18, 2026 at 11:45 AM
jama.com
Among patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day clinical outcomes compared with standard testing, despite providing faster guidance for antibiotic escalation or deescalation.

ja.ma/4uyTmCP
JAMA study: Rapid blood culture AST for GNB wasn't superior to standard AST. Population: 486 males, 364 females, median age 72. Intervention: 413 rapid AST, 437 standard AST. Findings: Alive w/o events: Rapid 47%, Standard 49%. DOOR probability: 48.8%.
May 26, 2026 at 9:29 PM
jama.com
📊 Research Summary: In patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day outcomes compared with standard testing, although it supported faster antibiotic adjustments.

#ESCMIDGlobal2026

ja.ma/41KZyuS
JAMA Research Summary: Fast Antimicrobial Susceptibility Testing. Key findings: Rapid AST had a 48.8% desirable outcome, not superior to standard. No difference in mortality. Trial involved 850 patients in Greece, India, Israel, Spain.
April 18, 2026 at 11:55 AM
jama.com
Presented at #ESCMIDGlobal2026: Among patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day clinical outcomes compared w/ standard testing, despite providing faster guidance for antibiotic escalation or deescalation.

ja.ma/4sILpcy
JAMA study on Rapid AST vs Standard AST for gram-negative bacteremia (GNB). Population: 486 males, 364 females, median age 72. Intervention: @number randomized, @number analyzed. Findings: Alive without events, Rapid AST @number%, Standard AST @number%.
April 19, 2026 at 10:00 AM
jama.com
Presented at #ESCMIDGlobal2026:

📊 Research Summary: In patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day outcomes compared with standard testing, although it supported faster antibiotic adjustments.

ja.ma/4cpmioY
JAMA Research Summary: Fast Antimicrobial Susceptibility Testing. Key findings: Rapid AST had a 48.8% desirable outcome, not superior to standard. No difference in mortality. Trial involved 850 patients in Greece, India, Israel, Spain.
April 19, 2026 at 12:00 PM
jama.com
📊 Research Summary: In patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day outcomes compared with standard testing, although it supported faster antibiotic adjustments.

ja.ma/4uQ0M56
JAMA summary on Fast AST for Gram-Negative Bacteremia. Rapid AST didn't improve overall 30-day patient outcomes vs standard testing, but sped up antibiotic changes (22 vs 36 hrs) & effective treatment for resistant infections. 850 patients (413 rapid, 437 standard).
June 1, 2026 at 1:18 PM
jama.com
Among patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day clinical outcomes compared with standard testing, despite providing faster guidance for antibiotic escalation or deescalation.

ja.ma/4efFl7l
JAMA study: Rapid AST for gram-negative bloodstream infections. N=850 (486M, 364F, med age 72). Rapid AST was not superior to standard AST for overall outcomes. Subgroup with carbapenem-resistant infections had greater discharge at 30 days. Alive without events: Rapid 47%, Std 49%. DOOR 48.8%.
June 1, 2026 at 1:18 PM